Differentiation between malignant transformation and tumour recurrence by 68Ga-bombesin and 18F-FDG-PET, in patients with low grade gliomas

Hellenic Journal of Nuclear Medicine

Volumn 11, Issue 3, 2008, Pages 149-152

  Seiz, Marcel ^a   Dimitrakopoulou Strauss, Antonia ^b   Schubert, Gerrit A ^a   Weinmann, Carolin ^a   Strauss, Ludwig G ^b   Eisenhut, Michael ^b   Tuettenberg, Jochen ^a  

^a UNIVERSITY OF MANNHEIM   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

18F FDG PET; 68Ga bombesin PET; Low grade gliomas; Malignant transformation

Indexed keywords

BOMBESIN GA 68; FLUORODEOXYGLUCOSE F 18; RADIOISOTOPE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ARTICLE; BRAIN SURGERY; CANCER CHEMOTHERAPY; CANCER GRADING; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLIOBLASTOMA; GLIOMA; GLIOSARCOMA; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; ISOTOPE LABELING; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; RECURRENT DISEASE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR RECURRENCE;

BOMBESIN; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; GALLIUM RADIOISOTOPES; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 60849116449     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Nelson SJ. Imaging of brain tumours after therapy. Neuroimaging Clin N Am 1999; 9: 801-819.
2. Valk PE, Dillon WP. Radiation injury of the brain. AJNR 1991; 12: 45-62.
3. Tofts PS, Benton CE, Weil RS. Quantitative analysis of whole-tumor Gd enhancement histograms predicts malignant transformation in low-grade gliomas. J Magn Imaging 2007; 25: 208-214.
4. Mason WP. Oligodendroglioma. Curr Treat Options Neurol. 2005; 7: 305-314.
5. Stege EM, Kros JM, De Bruin HG et al. Successful treatment of low-grade oligodendroglial tumors with chemotherapy regimen of procarbazine, lomustine and vincristine. Cancer 2005; 103: 802-809.
6. 18F-FET PET for Grading of Recurrent Gliomas: Is Evaluation of Uptake Knetics Superior to Standard Methods J Nucl Med 2006; 47: 393-403.
7. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol 1993; 3: 225-268.
8. 68Ga-labeled bombesin (6-14) analog. J Nucl Med. 2005; 46: 691-699.
9. 18F)fluoro-D-glucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin. Nucl Med Biol. 1990; 3: 273-279.
10. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med. 1991; 32: 623-648.
11. Stupp R, Mason WP, van den Bent MJ et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 978-996.
12. Ricci PE, Dungan DH. Imaging of low- and intermiediate grade gliomas. Semin Radiat Oncol 2001; 11: 103-112.
13. 1H NMR spectroscopic investigation. NMR Biomed 2005; 18: 371-382.
14. Minn H. PET and SPECT in low-grade ghoma. Eur J Radiol 2005; 56: 171-178.
15. 18F]fluorodeoxyglucose metabolism and positron emission tomography. Neurology 1982; 32: 1323-1329.
16. 18F-FDG PET in distinguishing recurrent brain tumour from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001; 96: 191-197.
17. De Witte O, Levivier M, Violon P et al. Prognostic value positron emission tomography with [18F]fluoro-deoxy-D-glucose in the low-grade glioma. Neurosurgery 1996; 39: 470-476.
18. 18F]fluorodeoxyglucose positron emission tomography. Ann Neurol 1991; 29: 347-355.
19. Jacobs AH, Kracht LW, Gossmann A et al. Imaging in Neurooncology. NeurRK 2005; 2: 333-347.
20. Ginsberg LE, Fuller GN, Hashmi M et al. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: Histopathological evaluation of a series. Sury Neurol 1998; 49: 436-440.
21. Scott JN, Brasher PM, Sevick RJ et al. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 2002; 59: 947-949.
22. White ML, Zhang Y, Kirby P, Ryken TC. Can tumor contrast enhancement be used as criterion for differentiating tumor grades of oligodendrogliomas? AJNR 2005; 26: 784-790.